Retrovirology · 2019
BLV: lessons on vaccine development.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdala Alejandro, Alvarez Irene, Brossel Hélène, Calvinho Luis, Carignano Hugo, Franco Lautaro, Gazon Hélène, Gillissen Christelle, Hamaidia Malik, Hoyos Clotilde, Jacques Jean-Rock, Joris Thomas, Laval Florent, Petersen Marcos, Porquet Florent, Porta Natalia, Ruiz Vanesa, Safari Roghaiyeh, Suárez Archilla Guillermo, Trono Karina, Willems Luc
Аннотация
Vaccination against retroviruses is a challenge because of their ability to stably integrate into the host genome, undergo long-term latency in a proportion of infected cells and thereby escape immune response. Since clearance of the virus is almost impossible once infection is established, the primary goal is to achieve sterilizing immunity. Besides efficacy, safety is the major issue since vaccination has been associated with increased infection or reversion to pathogenicity. In this review, we discuss the different issues that we faced during the development of an efficient vaccine against bovine leukemia virus (BLV). We summarize the historical failures of inactivated vaccines, the efficacy and safety of a live-attenuated vaccine and the economical constraints of further industrial development.